Atripla Online

How and where to order Atripla (Efavirenz with Emtricitabine and Tenofovir Disoproxil Fumarate) tablets online on the HIV Resource Center website:

Shop:	MEDS FOR SALE
Prices:	from $11.15 per pill
Discount:	5% coupon: 5OFF
Forms:	600 mg / 200 mg / 300 mg oral tablets
Quantity:	30, 60 pills
Type:	Viraday brand, Atripla generic
Payment:	Visa, Mastercard, AmEx, Bitcoin
Delivery:	Regular and express mail service
Shipping:	Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Atripla is a three-drug combination of efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.

Dosage and administration:

Testing: consult full prescribing information for important testing recommendations prior to initiation and during treatment with Atripla.

Recommended dosage in adults and pediatric patients weighing at least 40 kg: One tablet once daily taken orally on an empty stomach, preferably at bedtime.

Renal impairment: not recommended in patients with estimated creatinine clearance below 50 mL/min.

Hepatic impairment: not recommended in patients with moderate to severe hepatic impairment.

Dosage adjustment with rifampin coadministration: an additional 200 mg/day of efavirenz is recommended for patients weighing 50 kg or more.

Dosage forms and strengths:

Atripla tablets: 600 mg of efavirenz, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate.

Overdosage:

If overdose by Atripla occurs, the patient should be monitored for evidence of toxicity, and standard supportive treatment applied as necessary. Administration of activated charcoal may be used to aid removal of unabsorbed EFV. Hemodialysis can remove both FTC and TDF (refer to detailed information below) but is unlikely to significantly remove EFV from the blood.

Efavirenz: some patients accidentally taking 600 mg twice daily have reported increased nervous system symptoms. One patient experienced involuntary muscle contractions.

Emtricitabine: hemodialysis treatment removes approximately 30% of the FTC dose over a 3-hour dialysis period starting within 1.5 hours of FTC dosing (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). It is not known whether FTC can be removed by peritoneal dialysis.

Tenofovir DF: it is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of TDF, a 4-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.

Contraindications:

Previously demonstrated hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of Atripla.

Coadministration with voriconazole.

Coadministration with elbasvir/grazoprevir.

Warnings and precautions:

Rash: discontinue Atripla if severe rash develops.

Hepatotoxicity: monitor liver function tests before and during treatment in patients with underlying hepatic disease, including hepatitis B or C coinfection, marked transaminase elevations, or who are taking medications associated with liver toxicity. Among reported cases of hepatic failure, a few occurred in patients with no pre-existing hepatic disease.

Risk of adverse reactions or loss of virologic response due to drug interactions: Consult full prescribing information prior to and during treatment for important potential drug interactions. Consider alternatives to Atripla in patients taking other medications with a known risk of Torsade de Pointes or in patients at higher risk of Torsade de Pointes.

Serious psychiatric symptoms: immediate medical evaluation is recommended.

Nervous system symptoms: NSS are frequent, usually begin 1-2 days after initiating therapy, and resolve in 2-4 weeks. Dosing at bedtime may improve tolerability. NSS are not predictive of onset of psychiatric symptoms.

New onset or worsening renal impairment: can include acute renal failure and Fanconi syndrome. Prior to initiation and during use of Atripla, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. Avoid administering Atripla with concurrent or recent use of nephrotoxic drugs.

Embryo fetal toxicity: fetal harm may occur when administered to a pregnant woman during the first trimester. Avoid pregnancy while receiving Atripla and for 12 weeks after discontinuation.

Decreases in bone mineral density (BMD): consider assessment of BMD in patients with a history of pathological fracture or other risk factors for osteoporosis or bone loss.

Convulsions: use caution in patients with a history of seizures.

Lactic acidosis/severe hepatomegaly with steatosis: discontinue treatment in patients who develop symptoms or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity.

Immune reconstitution syndrome: may necessitate further evaluation and treatment.

Redistribution/accumulation of body fat: observed in patients receiving antiretroviral therapy.

Side effects, adverse reactions:

Most common adverse reactions of Atripla tablets (incidence greater than or equal to 10%) observed in an active-controlled clinical trial of EFV, FTC, and TDF are diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash.

To report suspected adverse reactions of Atripla (Efavirenz with Emtricitabine and Tenofovir Disoproxil Fumarate) pills, contact Gilead Sciences, Inc. or your local FDA.

Drug interactions:

Consult full prescribing information prior to and during treatment for important potential drug interactions.

HIV-1 protease inhibitors: Coadministration of Atripla with either lopinavir/ritonavir or darunavir and ritonavir increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity. Coadministration of this medication with either atazanavir or atazanavir and ritonavir is not recommended.

Related medications:

Emtricitabine, Tenofovir Disoproxil (Truvada)

Flibanserin 100 mg tablets

Use in specific populations:

Pregnancy: avoid pregnancy while receiving Atripla and for 12 weeks after discontinuation.

Lactation: breastfeeding is not recommended.

Females and males of reproductive potential: pregnancy testing and contraception are recommended.

Pediatrics: the incidence of rash was higher than in adults.

Where to buy Atripla online:

To purchase Atripla (Efavirenz with Emtricitabine and Tenofovir Disoproxil Fumarate) tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.

Here is a list of popular medications containing efavirenz with emtricitabine and tenofovir as main active pharmaceutical ingredients; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

Trade name of the drug	Pharmaceutical forms and doses	Companies
Atripla	Tablets, Film-Coated; Oral; Efavirenz 600 mg; Emtricitabine 200 mg; Tenofovir Disoproxil Fumarate 300 mg	Bristol-Myers Squibb Gilead Merck IDS Group
Teevir	Tablets, Film-Coated; Oral; Efavirenz 600 mg; Emtricitabine 200 mg; Tenofovir Disoproxil Fumarate 300 mg	Mylan
Viraday	Tablets, Film-Coated; Oral; Efavirenz 600 mg; Emtricitabine 200 mg; Tenofovir Disoproxil Fumarate 300 mg	Cipla